Roche awarded WHO prequalification for the cobas HPV test, increasing access to cervical cancer ...
? Every year, over 600,000 women worldwide are diagnosed with cervical cancer and over 340,000 die...
Stay updated with breaking news from Roche Global Access Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
? Every year, over 600,000 women worldwide are diagnosed with cervical cancer and over 340,000 die...
SOUTH SAN FRANCISCO (dpa-AFX) - Biopharmaceutical company Roche Holding AG (RHHBY), announced on Tuesday that its cobas HPV test for use on the cobas 6800/8800 Systems has been awarded the World
Every year, over 600,000 women worldwide are diagnosed with cervical cancer and over 340,000 die from this preventable disease, caused by infection with human papillomavirus (HPV). Nine out of 10 women
Prequalified status enables Roche to provide the Cobas HPV test to more low- and middle-income countries.
1 and the growing challenge of drug resistance is adding to the global health crisis WHO guidelines support the expansion of tuberculosis diagnostics in resource-limited countries, enabling patients to receive timely diagnosis leading to proper treatment, which benefits their recovery and slows the transmission of disease Roche’s Global Access Program aids clinicians in improving disease and patient management through increased access to innovative diagnostic solutions, allowing more patients to get test results promptly Basel, 09 July 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announ...